Below is our recent interview with Andrew Davies, CEO and Co-Founder at Texere Publishing:
Q: Could you provide our readers with a brief introduction to your company?
A: Since 2012, Texere has been launching media brands that connect with professional communities. We go beyond the remit of traditional scientific, technical, and medical (STM) publishers; Texere sparks new and insightful conversations, shares inspirational stories, explores challenges and controversies, and celebrates successes in a growing number of markets across the Healthcare, Pharmaceutical & Science sectors.
With hundreds of years of combined experience, we genuinely understand how healthcare is evolving to meet new needs, which direction “big pharma” and biotech are heading, and how increasingly advanced technology facilitates all forward momentum.
Q: Any highlights on your recent announcement?
A: It gave me great pleasure to announce externally, as well as to our valued staff members, that Texere had another record year in 2021, reporting an overall revenue increase of over 13.5 percent in spite of challenging market conditions. We’ve seen a tremendous increase in our digital offering ‒ digital sales experienced an impressive 66 percent growth ‒ and our continued geographic expansion means that our business in North America now represents over 50 percent of our revenue. Last year, we made a concerted effort to build on our digital expertise and invest in new talent, systems and processes, and as a result, our audience numbers rose by almost 14 percent and, on average, we saw a 45 percent increase in web traffic to our brand sites.
Q: Can you give us more insights into your offering?
A: Texere is a specialist niche media business. We create high quality content, pair it with beautifully designed products and support it with trusted print and digital distribution. The markets that we serve are vast and broad – pharma, biotech, ophthalmology, analytical science, diagnostic medicine, translational science… We continually assess areas of unmet need in the content space and, over the past three years, we have launched multiple, digital products serving niche sectors of our core markets, for example, cell and gene therapy. By focusing on highly-specialized fields, we have been able to further grow our product portfolio, audience and revenues.
Q: What can we expect from your company in next 6 months? What are your plans?
A: We have exciting plans for new product launches and for enhancements to our existing offering over the coming months. We don’t believe in standing still and want to reach out to new markets and further develop those we already serve. June 2022 marks our company’s 10 year anniversary. This is a major milestone for the business and something we could not have achieved without the support of our readers, clients and contributors.
Q: What is the best thing about your company that people might not know about?
A: We are passionate about telling the stories behind the science. When we launched back in 2012, our approach to content and design was potentially risky, but that is what differentiated us from our competitors and made us stand out in the market. To now hear eminent thought leaders in all of our core markets enthuse about our publications and claim publicly that we are making a difference has been one of our biggest achievements. We dared to do something different, and it’s working!Activate Social Media: